In vitro inhibitory activities of selected Australian medicinal plant extracts against protein glycation, angiotensin converting enzyme (ACE) and digestive enzymes linked to type II diabetes

Abstract

BackgroundThere is a need to develop potential new therapies for the management of diabetes and hypertension. Australian medicinal plants collected from the Kuuku I’yu (Northern Kaanju) homelands, Cape York Peninsula, Queensland, Australia were investigated to determine their therapeutic potential. Extracts were tested for inhibition of protein glycation and key enzymes relevant to the management of hyperglycaemia and hypertension. The inhibitory activities were further correlated with the antioxidant activities.MethodsExtracts of five selected plant species were investigated: Petalostigma pubescens, Petalostigma banksii, Memecylon pauciflorum, Millettia pinnata and Grewia mesomischa. Enzyme inhibitory activity of the plant extracts was assessed against α-amylase, α-glucosidase and angiotensin converting enzyme (ACE). Antiglycation activity was determined using glucose-induced protein glycation models and formation of protein-bound fluorescent advanced glycation endproducts (AGEs). Antioxidant activity was determined by measuring the scavenging effect of plant extracts against 1, 1-diphenyl-2-picryl hydrazyl (DPPH) and using the ferric reducing anti-oxidant potential assay (FRAP). Total phenolic and flavonoid contents were also determined.ResultsExtracts of the leaves of Petalostigma banksii and P. pubescens showed the strongest inhibition of α-amylase with IC50 values of 166.50 ± 5.50 μg/mL and 160.20 ± 27.92 μg/mL, respectively. The P. pubescens leaf extract was also the strongest inhibitor of α-glucosidase with an IC50 of 167.83 ± 23.82 μg/mL. Testing for the antiglycation potential of the extracts, measured as inhibition of formation of protein-bound fluorescent AGEs, showed that P. banksii root and fruit extracts had IC50 values of 34.49 ± 4.31 μg/mL and 47.72 ± 1.65 μg/mL, respectively, which were significantly lower (p < 0.05) than other extracts. The inhibitory effect on α-amylase, α-glucosidase and the antiglycation potential of the extracts did not correlate with the total phenolic, total flavonoid, FRAP or DPPH. For ACE inhibition, IC50 values ranged between 266.27 ± 6.91 to 695.17 ± 15.38 μg/mL.ConclusionsThe tested Australian medicinal plant extracts inhibit glucose-induced fluorescent AGEs, α-amylase, α-glucosidase and ACE with extracts of Petalostigma species showing the most promising activity. These medicinal plants could potentially be further developed as therapeutic agents in the treatment of hyperglycaemia and hypertension.Electronic supplementary materialThe online version of this article (doi:10.1186/s12906-016-1421-5) contains supplementary material, which is available to authorized users.

Mangosteen pericarp extract embedded in electrospun PVP nanofiber mats: physicochemical properties and release mechanism of &alpha;-mangostin

“…Antioxidant activities of the pure MPE, MF1, MF2, and MF3 nanofiber mats were determined based on the reduction of DPPH absorbance by calculating the percentage of antioxidant activity. 44 In vitro release study…”

α-Glucosidase and α- amylase inhibition potentials of ten wild Mexican species of Verbenaceae

“…The inhibitory activity (H) of the extracts was calculated as in Eq 1. H (%) = {1 -(Ac -As)/Ac}100 …………… (1) where Ac and As are the absorbance of the control (water instead of extract) and the extract, respectively. Values were expressed as halfmaximal concentration (IC 50 ) value.…”

“…Type 2 Diabetes mellitus (T2DM) is a chronic disease associated with a high concentration of blood glucose or hyperglycemia that can be produced by a deficient carbohydrate, lipid and protein metabolism [1]. T2DM affects an important proportion of the world population [2].…”

“…Hyperglycemia, in non-insulin dependent patients, is due to an increased starch breakdown by α-amylase and a high glucose absorption favored by the action of α-glucosidase [1][2][3]. The inhibition of these enzymes could reduce blood glucose levels and, therefore, decrease hyperglycemia linked to T2DM [4].…”

Emerging Applications of Fermented Fruit Enzyme Beverages as Nutraceutical, Functional Food, and Designer Food Products: A Review

“…Antiglycation activity was determined using glucose-induced protein glycation models and formation of protein-bound fluorescent advanced glycation endproducts (AGEs). Antioxidant activity was determined by measuring the scavenging effect of plant extracts against 1, 1-diphenyl-2-picryl hydrazyl (DPPH) and using the ferric reducing anti-oxidant potential assay (FRAP) 80 .…”